What Perrigo does

Perrigo Company plc is a Dublin-headquartered, NYSE-listed global consumer self-care company operating since 1887, structured as the largest US store-brand provider of over-the-counter (OTC) pharmaceuticals and infant formula and a Top 10 player in the European Consumer Self-Care market. Its core business model is a dual-track private-label and branded consumer health platform: store-brand OTC products containing the same active ingredients as national brands at 25-30% lower price points are manufactured and supplied to major retail chains across North America and Europe, while proprietary brands (Opill, Compeed, Solpadeine, NiQuitin, Mederma, ellaOne, Good Start, Reach, Firefly) address categories including oral contraception, foot care, pain relief, smoking cessation, scar treatment, emergency contraception, infant nutrition, and oral care. Manufacturing is conducted at cGMP-compliant facilities in the US (Allegan MI, Eau Claire WI, Grand Rapids MI, Bronx NY, Covington GA, Holland MI), the UK (Braunton), and Belgium (Wevelgem), with the Ranir oral care subsidiary headquartered in Grand Rapids and a regional European HQ in Dublin. In FY2025, Perrigo generated $4.25 billion in net sales, down 2.8% YoY, serving consumer self-care customers across 28 countries through retailer partnerships, pharmacy chains, e-commerce, and a company outlet store in Allegan, Michigan.

The company's near-term operating context is defined by a defensive turnaround posture: a $1.3 billion goodwill impairment charge in FY2025 largely tied to the 2023 Nestlé baby formula acquisition, a $80-100 million Operational Enhancement Program announced February 2026 with an accompanying 7% workforce reduction, an infant formula strategic review initiated November 2025, the April 2026 divestiture of the Dermacosmetics business to Karo Healthcare for up to €332.6 million, and a leadership transition in June 2026 following CEO Patrick Lockwood-Taylor's resignation (Albert A. Manzone appointed Interim CEO). Financial leverage remains elevated (1.24 debt-to-equity, market capitalization of approximately $1.49 billion against enterprise value of ~$4.93 billion), and the company faces ongoing securities class action litigation regarding the infant formula business alongside an IRS transfer-pricing appeal. Management is positioning the company around a "Three-S" plan (Stabilize, Streamline, Strengthen) while reinvesting in growth via new product launches including Good Start Canada Organic Infant Formula and a planned Compeed portfolio expansion in the second half of FY2026.

Name

Perrigo

Legal name

Perrigo Company plc

Website

https://perrigo.com

Company type

Public

Founded year

1887

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Perrigo is a Dublin-based global consumer self-care company and the largest US store-brand provider of OTC pharmaceuticals and infant formula, serving cost-conscious consumers and major retailers across 28 countries through a dual private-label and branded portfolio (Opill, Compeed, Good Start, Reach, NiQuitin).

Ownership category

akta.pro rank

Product category

Consumer Healthcare / Over-the-Counter Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Over-the-counter pharmaceuticals
• Private label OTC
• Infant formula nutrition
• Oral care products
• Consumer self-care

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices14 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. OTC Pharmaceutical Products: Perrigo manufactures and sells over-the-counter pharmaceuticals including pain relief, allergy, digestive health, and respiratory products. Revenue is generated through both private-label store brand arrangements with major retailers and proprietary branded products sold directly to consumers through retail channels.
2. Infant Formula and Nutritional Products: Sale of infant formula and nutritional products including store brand alternatives to Similac and Enfamil, as well as branded products like Good Start in Canada. Revenue from nutritional segment has been declining, contributing to overall company revenue challenges.
3. Oral Care Products: Manufacture and sale of oral care products including toothbrushes (Reach, Firefly, Infinity brands), floss picks, and mouth rinse. Products include private-label offerings and branded innovations with patented features.
4. Women's Health Products: Sales of women's health products including Opill (prescription-free oral contraceptive), ellaOne emergency contraception, and related reproductive health offerings in North America and Europe.
5. Skin Care and Personal Care: Sale of OTC dermatological and personal care products including Compeed (foot care), ACO brand (dermocosmetics, now divested), and Mederma scar treatment products.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Perrigo manufactures and distributes over-the-counter (OTC) pharmaceuticals, infant formula, oral care products, and women's health products as both private-label/store-brand offerings and proprietary branded products. The company supplies retailers with FDA-equivalent store-brand medications at 25-30% lower prices than national brands, while also marketing branded consumer self-care brands such as Opill, Good Start, Compeed, Solpadeine, NiQuitin, and ellaOne through retail and pharmacy channels.

Product overview

Perrigo Company plc is a leading global consumer self-care company and the largest U.S. store brand provider of OTC health and wellness products, also operating as a Top 10 player in the European Consumer Self-Care market. The company operates a dual business model combining private-label/store-brand OTC products with branded consumer health brands. The product portfolio spans multiple categories including Upper Respiratory, Pain and Sleep-Aids, Healthy Lifestyle, Skin Care, Digestive Health, Women's Health, Infant Nutrition, and Oral Self-Care. Key branded products include Opill® (OTC oral contraceptive), Mederma® (scar treatment), Compeed® (foot care), Solpadeine® (pain relief), NiQuitin® (smoking cessation), ellaOne® (emergency contraception), Good Start® and Advantage® (infant formulas). The store-brand portfolio offers FDA-standard equivalent products at 25-30% lower cost than national brands. The company recently reorganized its reporting segments into Self Care, Specialty Care, and Infant Formula categories effective Q1 2026, and completed the divestiture of its Dermacosmetics business in April 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Opill: OTC oral contraceptive product
• Compeed
• Solpadeine
• NiQuitin
• Mederma
• EllaOne
• Good Start
• Ranir
• Advantage
• Firefly
• Reach
• GoodSense
• Infinity
• Galaxy
• Bloom & Blossom
• Bronchenolo
• ACO
• Biodermal
• Emolium
• Iwostin

Products and services

• Opill The first and only FDA-approved over-the-counter progestin-only oral contraceptive pill for pregnancy prevention, available without a prescription. Sold to women of reproductive age through retail and pharmacy channels in North America.
• Good Start Infant Formula Infant formula products including Organic and non-GMO options providing complete nutrition for infants. Distributed in Canada through Amazon Canada and Loblaws, and in the US through retail partners.
• Advantage Infant Formula Non-GMO infant formula providing complete nutrition as a more affordable alternative to Similac PRO-ADVANCE. Sold through US retail and pharmacy channels.
• Mederma Scar treatment gel product for reducing the appearance of scars, sold to consumers through retail pharmacy and drug store channels in North America.
• Compeed Advanced blister and foot care products providing cushioning and protection. Distributed in European markets under this brand.
• Solpadeine Headache and pain relief medication containing paracetamol and caffeine. Distributed through UK and European retail and pharmacy channels.
• NiQuitin Nicotine replacement therapy products including patches and lozenges for smoking cessation. Distributed through European and international retail and pharmacy channels.
• ellaOne Emergency contraception pill for women of reproductive age. Distributed across European pharmacy chains including in UK, Germany, France, Italy, Spain, and other markets.
• Bronchenolo Respiratory relief product for cough and cold symptoms. Distributed through European retail and pharmacy channels.
• Store Brand OTC Products Private-label over-the-counter pharmaceutical and consumer health products including analgesics, allergy relief, digestive health treatments, and smoking cessation aids, sold under retailer store brands at 25-30% lower prices than national brand equivalents while meeting FDA standards.
• Ranir Oral Care Products Oral care products including manual and power toothbrushes (Reach, Infinity, Galaxy, Firefly, Polaris brands) and mouth rinses manufactured by Perrigo's wholly-owned subsidiary Ranir, sold through retail and private-label channels in North America and Europe.
• Nicotine Coated Mint Lozenges FDA-approved nicotine-coated mint lozenges for smoking cessation, launched in May 2023 to enhance user experience. Competes with Nicorette mini Lozenge.

Quantifiable outcome

• Store brand OTC products provide average savings of 25%-30% compared to national brand equivalents while meeting the same FDA standards
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Karo HealthcareminorOthers · 30 April 2026Perrigo completed the sale of its branded Dermacosmetics business to Karo Healthcare for total consideration of up to €332.6 million, consisting of €305.6 million in upfront cash and up to €27.0 million in contingent payments tied to net sales milestones. The divested brands include ACO, Biodermal, Emolium, and Iwostin, which generated approximately €120 million in net sales in 2025.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Prestige Consumer Healthcare: U.S.-focused OTC and consumer healthcare company specializing in store-brand and value brands across analgesics, GI, cough/cold and other self-care categories. Directly comparable as a private-label OTC manufacturer competing for similar retailer relationships and shelf space as Perrigo's store-brand franchise.
• Teva Pharmaceutical Industries: Global generic pharmaceutical manufacturer with a broad portfolio of OTC and generic prescription products across multiple therapeutic categories. Comparable to Perrigo as a high-volume manufacturer of off-patent drug formulations sold through retail and pharmacy channels.
• Viatris: Global off-patent pharmaceutical company combining generics, biosimilars, and consumer health products including OTC brands. Comparable to Perrigo across store-brand and branded OTC manufacturing at global scale.
• Apotex: Canadian privately-held generic pharmaceutical manufacturer producing finished dosage forms across multiple therapeutic categories. Comparable to Perrigo as a vertically-integrated generic manufacturer focused on cost-competitive supply to retailers and wholesalers.

Broad incumbents

• Haleon: Global consumer self-care company spun out of GSK, with leading OTC brands in pain relief, oral health, and wellness. Comparable to Perrigo as a major OTC manufacturer in similar categories but operating primarily through national brands rather than store-brand/private label.
• Bayer Consumer Health: OTC and consumer health division of Bayer, with leading brands in pain, allergy, and digestive health. Comparable to Perrigo as an OTC manufacturer across many of the same therapeutic categories, though with a branded rather than private-label focus.
• Church & Dwight: U.S. consumer packaged goods company with portfolios in personal care, oral care, and household products. Comparable to Perrigo as a CPG/OTC manufacturer with overlapping categories including oral care, where Perrigo competes via the Ranir subsidiary.
• Colgate-Palmolive: Global CPG leader in oral care, personal care, and home care products. Comparable to Perrigo specifically in the oral care category, where Perrigo's Ranir subsidiary competes with Colgate and other branded players for private-label and branded share.
• Sun Pharmaceutical Industries: India-based global specialty generics and OTC manufacturer with significant presence in the U.S. generics market. Comparable to Perrigo as a global manufacturer of generic finished dosage forms across multiple therapeutic categories.
• Procter & Gamble: Diversified global CPG company whose Oral-B brand competes with Perrigo's Ranir oral care portfolio. Comparable as a large incumbent in the oral care and personal care categories where Perrigo's branded subsidiaries operate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/PerrigoCareers
• Facebookfacebook.com/PerrigoCompanyPlc
• LinkedInlinkedin.com/company/perrigo

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A21 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perrigo